RSS-Feed abonnieren

DOI: 10.1055/s-0043-1770088
Cardiovascular Risk Factors in Premature Ovarian Insufficiency using Hormonal Therapy
Fatores de risco cardiovascular na insuficiência ovariana prematura em uso de terapia hormonalAutoren
Abstract
Objective Premature ovarian insufficiency (POI) is characterized by early hypoestrogenism. An increased risk of cardiovascular (CV) disease is a long-term consequence of POI. A challenge of hormone therapy (HT) is to reduce the CV risk.
Methods Cross-sectional study with lipid profile analysis (total cholesterol, LDL-C, HDL-C, VLDL-C and triglycerides), blood glucose levels and arterial blood pressure of women with POI using HT, compared with age and BMI-matched women with normal ovarian function (controls).
Results The mean age and BMI of 102 POI patients using HT and 102 controls were 37.2 ± 6.0 and 37.3 ± 5.9 years, respectively; 27.0 ± 5.2 and 27.1 ± 5.4 kg/m2. There wasn't difference between groups in arterial systolic and diastolic blood pressure, blood glucose levels, total cholesterol, LDL-C, VLDL-C and triglycerides. HDL-C levels were significantly higher in the POI group (56.3 ± 14.6 and 52 ± 13.9mg/dL; p = 0.03). Arterial hypertension was the most prevalent chronic disease (12% in the POI group, 19% in the control group, p = ns), followed by dyslipidemia (6 and 5%, in POI and control women).
Conclusion Women with POI using HT have blood pressure levels, lipid and glycemic profile and prevalence of hypertension and dyslipidemia similar to women of the same age and BMI with preserved gonadal function, in addition to better HDL levels.
Resumo
Objetivo A insuficiência ovariana prematura (IOP) é caracterizada pelo hipoestrogenismo precoce. Risco aumentado de doença cardiovascular (CV) é uma consequência a longo prazo da IOP e um desafio da terapia hormonal (TH) é reduzir o risco CV.
Métodos Estudo transversal com análise do perfil lipídico (colesterol total, LDL-C, HDL-C, VLDL-C e triglicerídeos), glicemia e pressão arterial de mulheres com IOP em uso de TH, em comparação a mulheres com função ovariana normal (controles) pareadas por idade e IMC.
Resultados A média de idade e IMC de 102 pacientes com IOP em uso de TH e 102 controles foi de 37,2 ± 6,0 e 37,3 ± 5,9 anos, respectivamente; 27,0 ± 5,2 e 27,1 ± 5,4 kg/m2. Não houve diferença entre os grupos na pressão arterial sistólica e diastólica, glicemia, colesterol total, LDL-C, VLDL-C e triglicerídeos. Os níveis de HDL-C foram significativamente maiores no grupo IOP (56,3 ± 14,6 e 52 ± 13,9mg/dL; p = 0,03). A hipertensão arterial foi a doença crônica mais prevalente (12% no grupo POI, 19% no grupo controle, p = ns), seguida da dislipidemia (6 e 5%, no grupo POI e controle).
Conclusão Mulheres com IOP em uso de TH apresentam níveis pressóricos, perfil lipídico e glicêmico e prevalência de hipertensão e dislipidemia semelhantes às mulheres da mesma idade e IMC com função gonadal preservada, além de melhores níveis de HDL.
Keywords
premature ovarian insufficiency - cardiovascular disease - secondary amenorrhea - hormonal therapy - cardiometabolic risk factorsPalavras-chave
insuficiência ovariana prematura - doença cardiovascular - amenorreia secundária - terapia hormonal - fatores de risco cardiometabólicosContributors
All authors were involved in the design and interpretation of the analyses, contributed to the writing of the manuscript, and read and approved the final manuscript.
Publikationsverlauf
Eingereicht: 11. September 2022
Angenommen: 10. April 2023
Artikel online veröffentlicht:
21. Juli 2023
© 2023. Federação Brasileira de Ginecologia e Obstetrícia. This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Revinter Publicações Ltda.
Rua do Matoso 170, Rio de Janeiro, RJ, CEP 20270-135, Brazil
-
References
- 1 Federação Brasileira das Associações de Ginecologia e Obstetrícia (FEBRASGO). Insuficiência ovariana prematura. São Paulo: FEBRASGO; 2021. . (Protocolo FEBRASGO-Ginecologia, n. 26/ Comissão Nacional Especializada em Ginecologia Endócrina)
- 2 Webber L, Davies M, Anderson R. et al; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod 2016; 31 (05) 926-937
- 3 Cooper AR, Baker VL, Sterling EW, Ryan ME, Woodruff TK, Nelson LM. The time is now for a new approach to primary ovarian insufficiency. Fertil Steril 2011; 95 (06) 1890-1897
- 4 Giri R, Vincent AJ. Prevalence and Risk Factors of Premature Ovarian Insufficiency/Early Menopause. Semin Reprod Med 2021; ••• : Epub ahead of print
- 5 de Almeida DM, Benetti-Pinto CL, Makuch MY. Sexual function of women with premature ovarian failure. Menopause 2011; 18 (03) 262-266
- 6 Benetti-Pinto CL, de Almeida DM, Makuch MY. Quality of life in women with premature ovarian failure. Gynecol Endocrinol 2011; 27 (09) 645-649
- 7 Løkkegaard E, Jovanovic Z, Heitmann BL, Keiding N, Ottesen B, Pedersen AT. The association between early menopause and risk of ischaemic heart disease: influence of Hormone Therapy. Maturitas 2006; 53 (02) 226-233
- 8 Podfigurna-Stopa A, Czyzyk A, Grymowicz M. et al. Premature ovarian insufficiency: the context of long-term effects. J Endocrinol Invest 2016; 39 (09) 983-990
- 9 Rivera CM, Grossardt BR, Rhodes DJ. et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause 2009; 16 (01) 15-23
- 10 Muka T, Oliver-Williams C, Kunutsor S. et al. Association of Age at Onset of Menopause and Time Since Onset of Menopause With Cardiovascular Outcomes, Intermediate Vascular Traits, and All-Cause Mortality: A Systematic Review and Meta-analysis. JAMA Cardiol 2016; 1 (07) 767-776
- 11 Archer DF. Premature menopause increases cardiovascular risk. Climacteric 2009; 12 (Suppl 1): 26-31
- 12 Daan NM, Muka T, Koster MP. et al. Cardiovascular Risk in Women With Premature Ovarian Insufficiency Compared to Premenopausal Women at Middle Age. J Clin Endocrinol Metab 2016; 101 (09) 3306-3315
- 13 Hamoda H. British Menopause Society and Women's Health Concern. The British Menopause Society and Women's Health Concern recommendations on the management of women with premature ovarian insufficiency. Post Reprod Health 2017; 23 (01) 22-35
- 14 Faubion SS, Kuhle CL, Shuster LT, Rocca WA. Long-term health consequences of premature or early menopause and considerations for management. Climacteric 2015; 18 (04) 483-491
- 15 Kalantaridou SN, Naka KK, Papanikolaou E. et al. Impaired endothelial function in young women with premature ovarian failure: normalization with hormone therapy. J Clin Endocrinol Metab 2004; 89 (08) 3907-3913
- 16 Roeters van Lennep JE, Heida KY, Bots ML, Hoek A. collaborators of the Dutch Multidisciplinary Guideline Development Group on Cardiovascular Risk Management after Reproductive Disorders. Cardiovascular disease risk in women with premature ovarian insufficiency: A systematic review and meta-analysis. Eur J Prev Cardiol 2016; 23 (02) 178-186
- 17 Gulhan I, Bozkaya G, Uyar I, Oztekin D, Pamuk BO, Dogan E. Serum lipid levels in women with premature ovarian failure. Menopause 2012; 19 (11) 1231-1234
- 18 Podfigurna A, Stellmach A, Szeliga A, Czyzyk A, Meczekalski B. Metabolic Profile of Patients with Premature Ovarian Insufficiency. J Clin Med 2018; 7 (10) 374-384
- 19 Alberti KG, Eckel RH, Grundy SM. et al. Harmonizing the metabolic syndrome: a join interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention. Circulation 2009; 120 (16) 1640-1645
- 20 Gunning MN, Meun C, van Rijn BB. et al; CREW consortium. The cardiovascular risk profile of middle age women previously diagnosed with premature ovarian insufficiency: A case-control study. PLoS One 2020; 15 (03) e0229576
- 21 Koh KK, Cardillo C, Bui MN. et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation 1999; 99 (03) 354-360
- 22 Sumino H, Ichikawa S, Itoh H. et al. Hormone replacement therapy decreases insulin resistance and lipid metabolism in Japanese postmenopausal women with impaired and normal glucose tolerance. Horm Res 2003; 60 (03) 134-142
- 23 Machura P, Grymowicz M, Rudnicka E. et al. Premature ovarian insufficiency - hormone replacement therapy and management of long-term consequences. Przegl Menopauz 2018; 17 (03) 135-138
- 24 Papagianni V, Deligeoroglou E, Makrakis E, Botsis D, Creatsas G. Response to hormonal treatment of young females with primary or very premature ovarian failure. Gynecol Endocrinol 2011; 27 (05) 291-299
- 25 Gökmen O, Yapar Eyi EG. Hormone replacement therapy and lipid-lipoprotein concentrations. Eur J Obstet Gynecol Reprod Biol 1999; 85 (01) 31-41
- 26 Vita JA, Keaney Jr JF. Hormone replacement therapy and endothelial function: the exception that proves the rule?. Arterioscler Thromb Vasc Biol 2001; 21 (12) 1867-1869
- 27 Munro MG, Critchley HOD, Fraser IS. FIGO Menstrual Disorders Committee. The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisions. Int J Gynaecol Obstet 2018; 143 (03) 393-408
- 28 Ferreira VA, Magalhães R. Obesidade no Brasil: tendências atuais. Rev Port Saude Publica 2006; 24 (02) 71-81
- 29 Mozaffarian D, Benjamin EJ, Go AS. et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation 2015; 131 (04) e29-e322 Erratum in: Circulation. 2016;133(8):e417
- 30 Ivanisević M, Vujović S, Drezgić M. [Effects of estro-progestagens on lipid and hormonal profiles in women with premature primary ovarian failure]. Med Pregl 2005; 58 (5-6): 296-300
- 31 Herrington DM, Espeland MA, Crouse III JR. et al. Estrogen replacement and brachial artery flow-mediated vasodilation in older women. Arterioscler Thromb Vasc Biol 2001; 21 (12) 1955-1961
- 32 Mercuro G, Zoncu S, Saiu F, Mascia M, Melis GB, Rosano GM. Menopause induced by oophorectomy reveals a role of ovarian estrogen on the maintenance of pressure homeostasis. Maturitas 2004; 47 (02) 131-138
- 33 Bădoi D, Crauciuc E, Rusu L, Luca V. Therapy with climara in surgical menopause. Rev Med Chir Soc Med Nat Iasi 2012; 116 (03) 828-833
- 34 Freitas ATA, Donovan Giraldo AE, Pravatta Rezende G, Yela DA, Jales RM, Benetti-Pinto CL. Body composition in women with premature ovarian insufficiency using hormone therapy and the relation to cardiovascular risk markers: A case-control study. Clin Endocrinol (Oxf) 2021; 94 (01) 111-118
- 35 Cai WY, Luo X, Wu W. et al. Metabolic differences in women with premature ovarian insufficiency: a systematic review and meta-analysis. J Ovarian Res 2022; 15 (01) 109